- Home
- WIA vs DRUG Comparison
WIA vs DRUG Comparison
Compare WIA & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- DRUG
- Stock Information
- Founded
- WIA 2003
- DRUG 2019
- Country
- WIA United States
- DRUG United States
- Employees
- WIA N/A
- DRUG N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- DRUG Pharmaceuticals and Biotechnology
- Sector
- WIA Finance
- DRUG Health Care
- Exchange
- WIA Nasdaq
- DRUG Nasdaq
- Market Cap
- WIA 192.9M
- DRUG 199.7M
- IPO Year
- WIA N/A
- DRUG N/A
- Fundamental
- Price
- WIA $8.39
- DRUG $28.37
- Analyst Decision
- WIA
- DRUG Strong Buy
- Analyst Count
- WIA 0
- DRUG 7
- Target Price
- WIA N/A
- DRUG $83.25
- AVG Volume (30 Days)
- WIA 39.2K
- DRUG 56.6K
- Earning Date
- WIA 01-01-0001
- DRUG 08-13-2025
- Dividend Yield
- WIA 12.29%
- DRUG N/A
- EPS Growth
- WIA N/A
- DRUG N/A
- EPS
- WIA N/A
- DRUG N/A
- Revenue
- WIA N/A
- DRUG N/A
- Revenue This Year
- WIA N/A
- DRUG N/A
- Revenue Next Year
- WIA N/A
- DRUG N/A
- P/E Ratio
- WIA N/A
- DRUG N/A
- Revenue Growth
- WIA N/A
- DRUG N/A
- 52 Week Low
- WIA $7.56
- DRUG $0.93
- 52 Week High
- WIA $8.91
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- WIA 65.05
- DRUG 52.64
- Support Level
- WIA $8.25
- DRUG $23.18
- Resistance Level
- WIA $8.46
- DRUG $26.86
- Average True Range (ATR)
- WIA 0.07
- DRUG 1.90
- MACD
- WIA 0.01
- DRUG 0.24
- Stochastic Oscillator
- WIA 70.37
- DRUG 84.13
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.